“In 2021, we had 114 import-substituting veterinary drugs authorized. In 2022, there were 117 of those. In September 2023, the number had already reached 65 new positions. The total of 94 new veterinary drugs is expected to be registered by the end of the year. They will be released into the commercial market by our colleagues at Rosselkhoznadzor after the manufacturers have completed registration procedures,” said Maria Novikova.
Furthermore, she pointed out that there is a vigorous process of import substitution in the domestic market.
“As for the volumes of most popular drugs, such as antimicrobial and antiparasitic drugs, that our manufacturers are able to cover, they confirm their willingness to completely substitute those at existing capacities. Speaking of immunobiologicals, we are able to fully cover the needs for destructive and economically significant animal diseases. There are certain challenges in this direction, but we have been facing them successfully. Both our public and private productions successfully reorganize existing capacities and introduce new ones in order to be able to provide for the necessary volumes of previously imported products,” said Maria Novikova.
She also highlighted the growing interest among pharmaceutical companies to enter the animal health market. Reminder: A law on the simplified registration procedure for human drugs to be used in the treatment of pets (FZ-171) came into force on September 1, 2023. Besides that, Novikova pointed out the growing enthusiasm shown by the “friendly countries”.
